Eliquis
Eliquis Price range: $ 60,00 through $ 320,00
Back to products
Empagliflozin
Empagliflozin Price range: $ 153,00 through $ 727,00

Elocon

Price range: $ 40,00 through $ 190,00

Elocon is a potent topical corticosteroid designed to effectively manage a variety of inflammatory skin conditions. The active ingredient, mometasone furoate, works by significantly reducing redness, swelling, and irritation at the source. It is widely used to provide rapid relief from the persistent symptoms of eczema, psoriasis, and various types of dermatitis. This medication helps to alleviate uncomfortable itching and inflammation, promoting the natural healing process of affected skin areas. Available in different formulations, Elocon ensures targeted action to help you maintain healthy and clear skin.

Active substance: Mometasone
SKU: Elocon Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Elocon belongs to a class of medications known as medium-to-high potency topical corticosteroids. Prescribed by healthcare providers, it helps manage the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients requiring localized anti-inflammatory therapy.

This prescription-only topical agent contains mometasone furoate as its active pharmaceutical ingredient and is available in various topical formulations including ointment, cream, and lotion. Proper application and adherence to clinical guidelines ensure maximal therapeutic benefit while minimizing potential cutaneous or systemic side effects.

Active Ingredient Mometasone furoate (0.1%)
Therapeutic Class Topical Corticosteroid
Dosage Form Cream, Ointment, Topical Solution/Lotion
Route of Administration Topical
Primary Purpose Relief of inflammatory and pruritic dermatoses
Prescription Status Prescription (Rx) only

Clinical Overview & Pharmacological Profile

How the drug works

Mometasone furoate is a synthetic corticosteroid exhibiting anti-inflammatory, antipruritic, and vasoconstrictive properties. At the cellular level, corticosteroids diffuse across cell membranes and bind with high affinity to specific cytoplasmic glucocorticoid receptors. This receptor-ligand complex translocates into the cell nucleus, where it modulates gene transcription. Specifically, mometasone furoate induces the synthesis of lipocortins (phospholipase A2 inhibitory proteins). Lipocortins inhibit the enzyme phospholipase A2, thereby suppressing the release of arachidonic acid from membrane phospholipids. Because arachidonic acid is a necessary precursor to potent inflammatory mediators such as prostaglandins and leukotrienes, its inhibition effectively curtails downstream inflammatory cascades, vascular permeability, and edema formation within dermatological tissue.

What it’s used for

Elocon is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Approved clinical indications include moderate-to-severe plaque psoriasis, atopic dermatitis (eczema), allergic contact dermatitis, and seborrheic dermatitis affecting the skin or scalp. The topical ointment and cream formulations are tailored for specific cutaneous conditions; the ointment is typically preferred for dry, lichenified, or scaly lesions due to its emollient properties, whereas the cream or topical lotion is suited for moist, intertriginous, or hairy areas. Off-label administration for unapproved dermatological conditions must be evaluated exclusively by a licensed prescriber, as improper application on non-responsive conditions (such as viral or fungal cutaneous infections) may exacerbate underlying pathology.

What happens in the body

The extent of percutaneous absorption of topical corticosteroids is determined by multiple factors, including the integrity of the epidermal barrier, the vehicle formulation, and the use of occlusive dressings. Pharmacokinetic evaluations indicate that minimal systemic absorption occurs following topical application of intact, non-occluded skin. Following an eight-hour contact period of mometasone furoate cream or ointment on normal skin without occlusion, approximately 0.4% to 0.7% of the applied dose enters systemic circulation. Once absorbed systemically, corticosteroids bind to plasma proteins in varying degrees, are metabolized predominantly in the liver, and are excreted by the kidneys and in bile. The plasma half-life of systemically absorbed mometasone furoate varies based on metabolic pathways but remains low under standard non-occlusive topical administration.

First days of treatment

During the initial days of treatment, patients can anticipate a gradual reduction in cutaneous inflammation, erythema, and localized itching (pruritus). Clinical improvements frequently manifest within 24 to 48 hours following the initial application, depending on the severity and underlying cause of the dermatosis. It is crucial to monitor the treated site for signs of localized hypersensitivity, such as burning or stinging immediately following application. Early therapeutic responses should not lead to abrupt or unmonitored cessation if a structured tapering strategy has been recommended by the prescriber to prevent symptom rebound.

Signs of improvement

Evaluation of therapeutic efficacy relies on observable clinical parameters of skin recovery. Key indicators of improvement include a noticeable decrease in localized skin redness (erythema), reduced scaling or plaque thickness, diminishment of papules or vesicles, and substantial relief from pruritus. Complete resolution of dermatological lesions may require several days of continuous once-daily application. If no clinical improvement is observed within two weeks of initiating therapy, the diagnosis should be re-evaluated by a healthcare provider to exclude misdiagnosed fungal, bacterial, or viral skin infections.

Administration, Safety, & Practical Considerations

Dosing schedule

Elocon should be applied strictly as directed by a healthcare provider. The standard dosage administration involves applying a thin film of cream or ointment to the affected skin areas once daily. Rub gently until the preparation disappears into the skin. For the topical lotion formulation, a few drops should be applied once daily to affected areas, including hairy sites, and massaged lightly until absorbed. Occlusive dressings–such as plastic wrappings or tight-fitting bandages–should not be used unless explicitly directed by a physician, as occlusion markedly enhances systemic absorption and elevates the risk of hypothalamic-pituitary-adrenal (HPA) axis suppression. Treatment duration should be limited to the minimum time necessary to achieve clinical control, typically not exceeding two consecutive weeks without formal medical re-evaluation.

Adverse reactions

Adverse reactions associated with Elocon are predominantly localized to the site of application, though systemic adverse events may occur under specific conditions. Commonly reported local side effects include burning, stinging, pruritus, skin atrophy, skin fragility, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin maceration, secondary infection, striae, and miliaria. Systemic absorption of topical mometasone furoate can lead to reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing’s syndrome, hyperglycemia, and glucosuria. HPA axis suppression is more likely when large surface areas are treated, high concentrations are used under occlusion, or therapy is prolonged. Children are at greater risk of systemic toxicity due to their higher skin surface-to-body-mass ratio.

Compatibility with other medicines

Systemic drug interactions with topically applied mometasone furoate are uncommon due to low percutaneous absorption under normal conditions. However, concurrent application of other topical products, particularly those containing corticosteroids, keratolytic agents, or skin irritants, on the same anatomical area should be avoided unless managed by a physician. Concomitant use of systemic corticosteroids or potent CYP3A4 inhibitors (such as ketoconazole or ritonavir) may theoretically increase systemic exposure and heighten the risk of systemic corticosteroid toxicity if significant percutaneous absorption occurs. Always inform your healthcare provider of all concurrent topical and systemic medications, dietary supplements, and dermatological therapies being utilized.

Important precautions

Caution is warranted when administering Elocon to vulnerable patient populations and sensitive anatomical areas. Avoid application near the eyes, eyelids, or mucous membranes, as topical corticosteroids can exacerbate glaucoma or induce cataracts. Long-term continuous therapy should be avoided, particularly in pediatric patients, due to potential growth suppression and HPA axis dysfunction. In pregnant or nursing women, Elocon should be used only if the potential benefit justifies the potential risk to the fetus or infant; topical corticosteroids should not be applied directly to the breasts prior to breastfeeding. Patients with diabetes mellitus should exercise caution, as systemic absorption may influence glycemic control. If a secondary skin infection develops, appropriate antifungal or antibacterial therapy must be instituted.

If you skip a dose

If a dose of Elocon is missed, apply the forgotten amount as soon as it is remembered, provided it is not almost time for the next scheduled application. If the next application is due shortly, skip the missed dose and resume the regular once-daily regimen. Do not apply double amounts or increase application frequency to compensate for a missed application, as this increases the risk of local skin irritation and systemic absorption without improving therapeutic efficacy.

Storage and expiration

Elocon should be stored at controlled room temperature between 68°F and 77°F (20°C to 25°C), with excursions permitted between 59°F and 86°F (15°C to 30°C). Keep the container tightly closed when not in use. Do not freeze topical creams, ointments, or solutions. Store out of the reach and sight of children and pets. Do not use this medication past the expiration date printed on the tube, carton, or bottle, as active ingredient potency and vehicle stability cannot be guaranteed after expiration.

Common questions

Can Elocon be applied to the face or groin area?

Topical corticosteroids like Elocon should generally be avoided on facial, intertriginous, or groin areas unless specifically directed by a healthcare provider. The skin in these regions is thinner and significantly more susceptible to adverse effects such as skin atrophy, striae, and enhanced systemic absorption.

How long can Elocon be safely used continuously?

Continuous daily use of Elocon should generally not exceed two consecutive weeks unless monitored by a physician. Prolonged application increases the risk of local cutaneous atrophy and systemic suppression of the hypothalamic-pituitary-adrenal axis.

Does Elocon cause skin thinning (atrophy)?

Skin atrophy is a known localized risk associated with topical corticosteroid therapy, especially with prolonged use, application under occlusive dressings, or use on thin skin areas. Following proper application guidelines and limiting duration minimizes this risk.

Is Elocon safe to use during pregnancy?

Elocon should be used during pregnancy only if the potential benefits outweigh the potential risks to the fetus. It is assigned to risk categories indicating that extensive clinical trials in pregnant women are lacking, so prescription decision rests on professional medical assessment.

What should be done if no improvement is seen after two weeks of treatment?

If skin symptoms fail to improve or worsen after two weeks of consistent application, discontinue use and consult your healthcare provider. Re-evaluation may be necessary to rule out unmanaged fungal, bacterial, or viral skin infections.

In accordance with FDA requirements.

Information on this page is for reference and does not replace an assessment by a licensed healthcare professional.

Additional information
Dosage

1mg 5g

Package

1 tubes

,

2 tubes

,

3 tubes

,

4 tubes

,

5 tubes

,

6 tubes

,

7 tubes

,

8 tubes

,

9 tubes

,

10 tubes

Ενεργός Ουσία